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Abstract
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Phenothiazine and derivatives were tested for inhibition of SARS-CoV replication. Phenothiazine
slightly inhibited SARS-CoV replication in a neutral red (NR) uptake assay. Adding a propylamino
group to give promazine reduced virus yields (VYR assay) with an EC90 = 8.3 ± 2.8 µM, but without
selectivity. Various substitutions in the basic phenothiazine structure did not promote efficacy.
Phenazine ethosulfate was the most potent compound by VYR assay (EC90 = 6.1 ± 4.3 µM). All
compounds were toxic (IC50 = 6.6–74.5 µM) except for phenoxathiin (IC50 = 858 ± 208 µM) and
10-(alpha-diethylamino-propionyl) phenothiazine·HCl (IC50 = 195 ± 71.2 µM). Consequently, none
were selective inhibitors of SARS-CoV replication (SI values <1–3.3 µM). These data portended the
poor efficacy of promazine in a SARS-CoV mouse lung replication model. Intraperitoneal treatment
with promazine using a prophylactic (−4 h)/therapeutic regimen of 1, 10, or 50 mg/(kg day) did not
reduce virus lung titers at day 3, yet prolonged virus replication to 14 days. Similar therapeutic
promazine doses were not efficacious. Thus, promazine did not affect SARS-CoV replication in vitro
or in vivo, nor were any other phenothiazines efficacious in reducing virus replication. Therefore,
treating SARS infections with compounds like promazine is not warranted.
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1. Introduction
Severe acute respiratory syndrome (SARS) emerged in 2002 in the Guandong province of
southern China as a new infectious respiratory disease characterized by influenza-like
symptoms and signs, but with a very high mortality rate. The initial out-break of SARS infection
rapidly spread through the human population due to international travel, reaching nearly 30
countries by the middle of 2003 (De Clercq, 2006); this episode possibly being a portent of
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epidemics of the future. The over-all mortality rate was 10%, and up to 50% within the elderly
population (De Clercq, 2006). The epidemic resulted in about 8000 probable cases of SARS
with 800 deaths attributed to the virus infection. There were also four confirmed cases of SARS
in Ghangzou, China in late 2003 and early 2004 (Liang et al., 2004; Song et al., 2005). Two
subsequent outbreaks were contained rapidly and were due to the escape of the virus from
laboratories doing SARS-CoV research (Lim et al., 2006).
Because SARS appeared to be life-threatening and highly contagious, the resources of the
science community were quickly marshaled to gain a better understanding of the disease and
the etiological agent to facilitate the development of rational therapies for prophylaxis and
treatment (Weiss and Navas-Martin, 2005; De Clercq, 2006). Thus, the putative agent was
quickly identified as a corona-like virus (Peiris et al., 2003) and was soon shown to be the
etiological agent for SARS (Fouchier et al., 2003).
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Early in the SARS outbreak there was a concerted effort by many laboratories to evaluate
clinically approved drugs for efficacy against SARS-CoVto rapidly provide a treatment for
SARS infections in humans. For example, several laboratories have evaluated phenothiazine
and promazine (clinically approved antipsychotic drugs) and many derivatives of those two
classes of compounds for inhibition of SARS-CoV replication (Zhang and Yap, 2004; Barnard
et al., 2005; Hsieh et al., 2005). The positive data have prompted recommendations that these
types of drugs be considered as therapies for SARS infections or as lead compounds for
development of more potent derivatives. Data are now presented that confirm and extend the
in vitro anti-SARS-CoV efficacy previously reported, but showing in an in vivo model that
clinical use is contraindicated.

2. Materials and methods
2.1. Cells and virus
African green monkey kidney cells (Vero 76) were obtained from the American Type Culture
Collection (ATCC; Manassas, VA). The cells were grown in minimal essential medium (MEM)
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone Laboratories;
Logan UT). For antiviral assays, the serum was reduced to 2% and 50 µg/ml gentamicin added
to the medium.
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SARSCoV, strain Urbani (200300592), was obtained from the Centers for Disease Control
(Atlanta, GA), the Frankfurt strain was kindly provided by Jindrich Cinatl (Klinikum der J.W.
Goethe Universität, Frankfurt Am Main, Germany), the Toronto-2 strain was supplied by Heinz
Feldman (National Microbiology Laboratory, Winnipeg, Manitoba, Canada) and the CHUKW1 strain was received from Paul KS Chan (Chinese University of Hong Kong, China). All
strains were passaged in Vero 76 cells.
All experiments involving infectious SARS-CoV were carried out in BSL-3+ laboratories. All
personnel wore complete body protective coverings and HEPA-filtered powered air purifying
respirators.
2.2. Compounds
Promazine, phenoxathiin, 10-(1-ethyl-3-propyl-3-pyrrolidinyl-methyl)-phenothiazine·HCL,
10-(1-ethyl-3-pyrrolidiny-methyl)-phenothiazine·HCL, 10-(1-methyl-2-pyrrolidinymethyl)phenothiazine·HCL, chlorprothixene, 2-chloro-10-(3-chloropropanol)-10H-phenothiazine,
phenoxazine, phenothiazine, perphenazine, propionylpromazine·HCL, ethopropazine,
methotrimeprazine and acetopromazine were obtained from Sigma-Aldrich, Co. (St. Louis,
MO); 10-(1-ethyl-3-pyrrolidinymethyl)-phenothiazine·HCL and trifluopromazine·HCL were
from MP Biomedicals (Irvine, CA); trifluoperazine dimaleate was obtained from Calbiochem
Antiviral Res. Author manuscript; available in PMC 2009 August 1.
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(La Jolla, CA), and acetophenazine maleate was received from U.S.P.C., Inc. (Rockland, MD).
After solubilization in physiological saline (PSS) or dimethylsulphoxide (DMSO) for
chlorprothixene, phenoxazine, phenothiazine, all were diluted in PSS to the working
concentrations. The reference drug for the in vitro efficacy tests was calpain inhibitor IV
(Calbiochem). Mouse interferon-alpha (muIFN-α), the reference drug for the animal studies,
was provided by Kurt Berg (Panum Inst., IMMI, The IFN-Lab, Copenhagen, Denmark).
2.3. Neutral red (NR) uptake assay for determination of antiviral efficacy and compound
cytotoxicity
Compounds were tested at varying concentrations (four log10 or eight 1/2 log10 dilutions).
Virus and compound were added in equal volumes to near-confluent cell monolayers in 96well tissue culture plates. The multiplicity of infection ranged from 0.001 to 0.004 in order to
produce viral cytopathic effects (CPE) for each strain of virus in 100% of the cells in the virus
control wells within 3–4 days. The plates were incubated at 37 °C in a 5% CO2 atmosphere
until the cells in the virus control wells showed complete viral CPE as observed by light
microscopy. Each concentration of drug was assayed for virus inhibition in triplicate and for
cytotoxicity in duplicate. Six wells per plate were set aside as uninfected, untreated cell controls
and six wells per plate received virus only and represented controls for virus replication.
Calpain inhibitor IV was included as positive control drugs for each set of compounds tested.
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After examining the virus-infected controls, by light microscopy for viral CPE, CPE and
compound cytotoxicity were quantitated by NR assay. The NR assay was performed using a
method of Cavenaugh et al. (1990) modified by Barnard et al. (2004b). Briefly, medium was
removed from each well of a plate, 0.034% NR was added to the test medium in each well of
the plate, and the plate incubated for 2 h at 37 °C in the dark. The solution was removed from
the wells, rinsed and any remaining dye extracted using ethanol buffered with Sörenson’s
citrate buffer. Absorbances at 540/405 nm were read with a microplate reader (Opsys MR™,
Dynex Technologies, Chantilly, VA). Absorbance values were expressed as percents of
untreated controls and EC50, IC50 and SI values were calculated as described previously
(Barnard et al., 1997a).
2.4. Virus yield reduction assay
Some compounds were evaluated in a more sensitive assay to confirm the results of the CPE
inhibition/NR uptake assays. Infectious virus yields from each well from a second CPE
inhibition assay were determined as previously described (Barnard et al., 2004a). After CPE
was determined, each plate was frozen at −80 °C and thawed. Sample wells at each
concentration tested were pooled and titered in Vero 76 cells for infectious virus by CPE assay.
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A 90% reduction in virus yield (EC90) was then calculated by linear regression analysis. This
represented a one log10 inhibition in titer when compared to untreated virus controls.
2.5. Virucidal assay
For compounds showing good antiviral inhibitory activity, a virucidal test was done to exclude
the possibility that the compounds inhibited the virus by physically inactivating or disrupting
the virion. The method of Barnard et al. (1997b) was used. Virus and compound were incubated
at room temperature for 1 h. Surviving virus was quantified by CPE assay and titers were
calculated as described previously by Barnard et al. (1997b). Concentrations of compound
tested bracketed the concentration determined to represent the EC50 from previous assays; each
concentration of test compound was assayed in duplicate.
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2.6.1. Animals—Specific pathogen-free BALB/c female mice (11–16 g, range varied with
each experiment) were obtained from Charles River Laboratories (Wilmington, MA). They
were quarantined for 1 week prior to use. Mice were fed standard mouse chow and tap water
ad libitum. Mouse studies approved by the Utah State University Animal Care and Use
Committee were carried out in an approved biosafety level 3 facility. Personnel entering the
facility wore powered air-purifying respirators (3M HEPA Air-Mate; 3M, Saint Paul, MN).
For the infectious disease experiments, mice were housed in bonneted filter-topped cages
placed within a HEPA-filtered horizontal laminar flow ventilated animal rack.
2.6.2. Lung virus titer determinations—Each mouse lung was homogenized and varying
dilutions assayed for infectious virus in Vero 76 cells. Each lung homogenate was stored at
−80 °C until each supernatant fluid was titered by CPE assay.
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2.6.3. Experiment design—In one set of experiments, twenty mice per group were treated
by intraperitoneal (i.p.) injection with the appropriate dosage of compound or placebo (saline)
administered 4 h prior to infection of mice. After the 4 h pretreatment, the mice were sedated
with an i.p. injection of 100 mg/kg of Ketamine® and were infected intranasally (i.n.) with 50
µl of clarified virus lysate (2 × 103 50% cell culture infectious doses, strain Urbani). Treatments
continued 8, 32, and 56 h after virus exposure. Uninfected animals (three for each dose of
compound or placebo) were treated with the same dosages of drug or with placebo to serve as
toxicity controls. Fifteen animals from both the placebo-treated and drug-treated, infected
groups were sacrificed on day 3 post-virus exposure; the lungs were removed and assayed for
virus. The remaining mice were sacrificed on day 7 and the lungs were removed, weighed, and
titered for virus. This experiment was repeated using only the 50 and 10 mg/kg doses with
additional animals being sacrificed at day 14. Lung samples were taken at days 3, 7, and 14
from sacrificed animals for cytokine analysis and titration of virus in the lung homogenate.
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In another set of experiments, promazine was evaluated for therapeutic efficacy. Prior to
infection with virus, the mice were sedated with an i.p. injection of 100 mg/kg of Ketamine®
and were infected intranasally (i.n.) with 50 µl of clarified virus lysate described above. Ten
mice per group were treated i.p. with promazine at 1, 10, or 100 mg/kg or 15 animals were
given placebo (saline) administered one time 8 h post-virus exposure or injected 8, 32, and 56
h after virus exposure (qd × 3). Uninfected animals (three for each dose of compound or
placebo) were treated with the same dose of drug or with placebo to serve as toxicity controls.
Ten animals from both the placebo-treated and seven animals from the drug-treated, infected
groups were sacrificed on day 3 post-virus exposure; the lungs were removed and assayed for
virus. The remaining mice were sacrificed on day 7 and the lungs were removed, weighed, and
titered for virus.
2.6.4. Histopathology—Lung sections were fixed in 10% formalin and then shipped to the
Utah State Veterinary Diagnostic Laboratory (Logan, UT) for processing (sectioning and
hematoxylin and eosin staining) and descriptive analysis.
2.6.5. Cytokine analysis—Lung samples were taken at 3, 7, 14 days post-virus exposure
and homogenized in MEM with 10% FBS. Samples were held frozen at −80 °C, then thawed
and equilibrated to 50 mg/mL. Samples were then tested for IL-1α, IL-1β, IL-2, IL-3, IL-4,
IL-6, IL-9, IL-10, IL-12, MCP-1, TNF-α, MIP-1α, GM-CSF and RANTES using the Q-Plex™
mouse cytokine array screen (Quansys Bioscience, Logan, UT). This cytokine screen is a
quantitative ELISA-based test with 14 distinct capture antibodies absorbed to each well of a
96-well plate in a defined array. Cytokines are detected and quantified by relative luminescence
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of each spot in the array. Values (pg/ml) were calculated using software developed by Quansys
based on the standard curve run concurrent with the assay.
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2.6.6. Statistical analysis—Differences in mean lung virus titers were evaluated by the
analysis of variance. For cytokine level analysis, Wilcoxon pair-wise comparisons between
test groups were done using “jmp 6.0 Statistical Discovery™ (SAS, Cary, NC).

3. Results
3.1. In vitro antiviral activity of phenazines and phenothiazines
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A number of phenazines and phenothiazines were tested for efficacy against SARS-CoV
(Urbani strain) replication in Vero 76 cells (Table 1). EC50 values ranged from 763 µM
(phenoxathiin) to 5.2 µM (phenazine ethosulfate) by NR assay. Most compounds exhibited
considerable toxicity with the exception of phenoxathiin and 10-(alphadiethylaminopropionyl)phenothiazine·HCL. The most potent inhibitor by virus yield reduction
assay was phenazine ethosulfate (EC90 = 6.1 µM). Promazine, a compound reported to inhibit
SARS-CoV (Zhang and Yap, 2004;Hsieh et al., 2005) also reduced virus yields with an
EC90 = 8.3 µM. In addition, promazine also inhibited other strains of SARS-CoV at similar
concentrations (Table 2) as detected by NR assay or by virus yield reduction assays. Most of
the other compounds tested against the other SARS-CoV strains were also inhibitory at similar
concentrations using either assay with the exception of 10-(1-methyl-2-pyrrolidinymethyl)phenothiazine-HCl. The antiviral activity shown in Table 1 was not due to virucidal activity,
at least for promazine, since virus exposure to promazine for 1 h at 25 °C did not result in virus
titer reduction (data not shown). The least toxic compound evaluated was phenoxathiin
(IC50 = 858 µM). Propionylpromazine·HCL, 2-chloro-10-(3-chloropropanol)-10Hphenothiazine, and phenoxazine were essentially inactive since the concentrations at which
cytotoxic effects were detected in cells were less than the concentrations detected that inhibited
virus replication. The protease inhibitor, calpain IV (positive drug control), inhibited virus
replication as expected (Barnard et al., 2004a).
3.2. Structure activity relationships
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Some structure-activity relationships could be established from the data (Fig. 1A and B).
Phenothiazine moderately inhibited SARS-CoV replication in Vero cells by neutral red (NR)
uptake assay (EC50 = 21.5 µM), but the addition of a propylamino group to phenothiazine to
give promazine resulted in a twofold increase in inhibition of SARS-CoV replication by NR
assay (EC50 = 10.8 µM, EC90 =10 µM) (Fig. 1A). In addition, derivatives of phenothiazine
with side chains that enhanced solubility or had side chains of electron withdrawing ring
structures (trifluoperazine, acetophenazine, perphenazine) were also more inhibitory of SARSCoV replication (EC90 = 8.4–10.2 µM), suggesting that these compounds may act as soluble
prodrugs of phenothiazine (Fig. 1B). This effect seemed to be abrogated if methoxy, acetyl or
propionyl groups were added to the two position of the basic ring structure to the Substituting
N with O in the phenothiazine nucleus to get phenoxathiin resulted in a much less potent and
much less toxic compound (phenoxathiin EC50 = 763 µM vs. EC50 phenothiazine = 21.5 µM).
However, substituting the S group in phenothiazine with O resulted in a less potent compound,
phenoxazine, which was also less toxic. The nitrogen in the phenothiazine basic ring structure
may not be essential for antiviral activity since its removal from the ring, as in for example,
chlorprothixene, resulted in inhibition of virus replication similar to that detected with
promazine.
3.3. In vivo antiviral activity
Treatment of mice with promazine at 1, 10 or 50 mg/(kg day) (−4 h, then 8, 32, 56 h after virus
exposure) resulted in no significant reduction of viral replication at day 3 (Table 3) in the lungs
Antiviral Res. Author manuscript; available in PMC 2009 August 1.
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of mice. The duration of virus replication in the lungs was significantly prolonged by each drug
treatment (−4 h, then 8, 32, 56 h after virus exposure); virus was detected in mice treated with
50 mg/kg and 10 mg/kg promazine at day 7 and at day 14. In contrast, in placebo-treated,
infected mice, the infection in the lungs was cleared by day 7 as has previously been shown
by others (Subbarao et al., 2004;Barnard et al., 2006). Despite the fact that virus persisted to
day 14 in promazine-treated mice, histopathogical examination of lungs from treated, infected
animals showed no signs of pathology consistent with a virus lung infection or consistent with
drug-induced cytotoxicity. Treating mice with 100 mg/(kg day) promazine (−4 h, then 8, 32,
56 h after virus exposure) was lethal to all mice by day 3 (Table 3). For reference, the reported
LD50 of promazine given to mice i.p. is 140 mg/(kg day) (Yen and Day, 1965). Mice were also
treated therapeutically with promazine. Treatment of mice with promazine at 100 mg/(kg day)
beginning 8 h after virus exposure was somewhat lethal as well; most animals died between
day 3 and day 7 (Table 4). All doses of promazine used therapeutically did not inhibit virus
replication in the lungs. Although the 10 mg/kg dose administered once a day either one time
or three times beginning 8 h after virus exposure did seem to slightly increase the amount of
virus recovered from lungs at day 3 compared to placebo, neither the 10 or 1 mg/kg doses
significantly prolonged virus infection as happened with the more frequent dosing schedule.
The 100 mg/kg dose killed all the control animals as well as the infected, treated animals by
day 7.
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SARS-CoV infection (placebo-treated, uninfected mice) caused a significant increase (p <
0.05) in the production of cytokines IL1-α, IL1-β, IL-4, IL-10, IL-12, MIP-1a, GM-CSF and
RANTES when compared to untreated, infected mice (Fig. 2). In uninfected mice, promazine
treatment alone caused a significant increases (P < 0.05 to P < 0.005) in IL1-α, IL1-β, IL-2
(50 mg/kg dose only), IL-3, IL-4, IL-9, IL-10, IL-12, TNF-alpha (50 mg/kg dose only), MIP-1
(50 mg/kg dose only), and RANTES, but not in IL-6, MCP-1, or GM-CSF, compared to
uninfected, untreated mice. Interestingly, promazine administered to infected mice at 50 mg/
kg seemed to promote much higher levels of IL-6 than was detectable in untreated, infected
mice or in uninfected mice treated with promazine. In infected animals treated with 50 mg/kg
promazine, RANTES titers were significantly lower (P < 0.05) than in the lungs of untreated,
infected mice. Promazine treatment of infected mice did not significantly affect other cytokines
levels in compared to untreated, infected mice. Cytokine levels in lung samples from mice
sacrificed 7 or 14 days post-infection were not significantly different when comparing treated,
infected mice and untreated, infected mice (data not shown) and by day 14 there were no
detectable increases in cytokine levels, regardless of treatment (data not shown).

4. Discussion
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In some reviews of antiviral therapy for SARS-CoV (Chan et al., 2003; Cinatl et al., 2005), it
has been suggested that promazine warrants further investigation as a potential treatment for
SARS-CoV infections based on the studies of Zhang and Yap, 2004; Barnard et al., 2005;
Hsieh et al., 2005). However in the studies presented here, in which the in vitro assays were
repeated four times using independent experiments to confirm all EC50 and IC50 values unlike
the data reported in other studies, we were unable to show any convincing antiviral data for
promazine or related compounds nor were we able to show efficacy of promazine in an animal
model. In fact, it is likely that the cytotoxic properties of the compounds accounted for any
slight in vitro inhibition of virus detected in the current studies.
However, an alternative explanation for the slight inhibitory activity of the phenothiazines
might be the inhibition of the SARS-CoV main protease. Three phenazines were predicted to
be inhibitors of the SARS-CoV main protease through docking predictions and virtual
screening. When these compounds were actually evaluated in enzymatic assays, the three
phenothiazines inhibited the enzyme activity by 11–15% (Liu et al., 2005). In addition,
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promazine, a phenothiazine, might also inhibit the SARS-CoV main protease. Zhang and Yap
(2004) in a computational study have shown that promazine can bind to amino acid residues
in the Domain I of the protease. However, the binding affinity would probably not be sufficient
to cause effective inhibition of the enzyme.
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The observation that promazine promotes the induction of certain proinflammatory cytokines
in schizophrenics may actually account for the prolongation of virus infection in mice observed
in the current study when mice were pretreated with promazine. Treatment of schizophrenics
with promazine seemed to induce some proinflammatory cytokines such as IL-6 and TNF-α,
which in turn stimulated highly reactive oxygen species (ROS) (Kaminska et al., 2003).
Induction of proinflammatory cytokines also occurs in many viral respiratory infections
including SARS (Xu and Gao, 2004; Barnard et al., 2006). Glass et al. (2004) found that SARSCoV infection in mice was characterized by a proinflammatory cytokine storm, including the
induction of IL-6 and TNF-α. We have found that ribavirin exacerbates the SARS-CoVinduced cytokine storm leading to a prolongation of viral replication in the lungs of infected
animals (Barnard et al., 2006). In addition, promazine at 50 mg/(kg day) seemed to significantly
decrease RANTES expression, an important chemokine promoting neutrophil migration to the
SARS-CoV infection site (Yen et al., 2006). Promazine, by suppressing RANTES levels might
have allowed virus to persist because of a lack of a good robust, neutrophil response to the
initial infection. Thus, the low-dose promazine treatments (50 mg/(kg day)) used in the current
study may have altered the SARS-CoV-perturbed cytokine levels resulting in a prolonged
infection and suppression of key chemokines necessary for clearance of virus after day 3,
leading to a persistent virus infection. However, the exacerbation of the infection may be
dependent on the frequency and the timing of treatment administration; less frequent dosing
without a pretreatment before virus exposure resulted in no prolongation of virus infection and
in no reduction of virus lung titers; RANTES expression was unaffected at lower doses
promazine.
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In summary, a number of phenothiazines very weakly inhibited the replication of four strains
of SARS-CoV in Vero cells, although this activity was probably due to the cytotoxicity of the
compounds tested. When one of the phenothiazines, promazine, was evaluated in a SARS-CoV
replication model in mice, toxicity was manifested at the highest dose of promazine treatment
administered i.p. (100 mg/(kg day)), resulting in death of all animals treated regardless of
dosing schedule or regimen. This observation validated the significant toxicity detected in vitro
with many of the phenothiazines evaluated in vitro. Even though a two-fold lower dose of
promazine was much less toxic in mice, virus lung titers were not reduced. Lower doses of
promazine (50 and 10 mg/(kg day)), when administered frequently and just prior to virus
exposure, significantly prolonged the infection. Given the almost total lack of inhibition of
virus replication in mice except at one dose, the narrow concentration window between lethality
and survival and the potential for prolongation of virus infection in animals, promazine and its
prodrugs should not be considered potential therapies for SARS infections.
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Fig. 1.

Structure activity relationships associated with phenoxathiin, phenoxazine and selected
phenothiazines: (A) comparison of structure and SARS-CoV inhibitory activity of
phenoxathiin, phenoxazine and selected phenothiazines and (B) comparison of structures and
anti-SARS-CoV inhibitory activities of phenothiazines with side chains enhancing solubility.
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Fig. 2.

Cytokine levels detected from the lungs of uninfected and infected mice with or without
promazine treatment at day 3 post-virus exposure. Data represents cytokine levels from the
lungs of individual mice with a bar indicating the average cytokine levels from each treatment
group (*P < 0.05, **P < 0.005).
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10.8 ± 8.1
10.8 ± 6.7
763 ± 475
9.5 ± 5.7
13.1 ± 8.8
93.5 ± 112.9
21.0 ± 11.0
19.0 ± 8.1
7.3 ± 4.7
6.6 ± 3.3
11.9 ± 5.6
24.3 ± 15.6
30.5 ± 27.5
13.3 ± 5.8
9.7 ± 1.2
23.0 ± 11.0
5.2 ± 2.9
a21.5 ± 8.1
a89.5 ± 14.8
a2.6 ± 1.4

EC50 (µM)

Neutral red uptake assay

13.5 ± 6.2
3.7 ± 1.3
858 ± 208
18.3 ± 3.4
29.5 ± 8.7
195 ± 71.2
37.8 ± 1.8
26.0 ± 10.8
9.5 ± 3.1
13.2 ± 1.6
39.9 ± 0.2
19.3 ± 2.2
61.3 ± 34.7
18.0 ± 5.6
15.8 ± 3.4
20.8 ± 8.1
6.6 ± 4.71
56.5 ± 61.5
74.5 ± 20.2
24.7 ± 7.0

IC50 (µM)
1.2
1.3
1.1
1.9
2.3
2.1
1.8
1.4
1.3
2.0
3.3
<1
2.0
1.4
1.6
<1
1.3
2.6
<1
9.4

SI
8.3 ± 2.8
10.3 ± 5.4
752 ± 497
10.4 ± 4.2
11.0 ± 3.9
203 ± 136
21.5 ± 14.6
12.3 ± 1.7
10.2 ± 4.4
10.0 ± 5.0
16.9 ± 9.7
a13.7 ± 0.6
a42.0 ± 1.0
12.8 ± 1.9
a8.4 ± 5.3
27.0 ± 16.8
6.1 ± 4.3
NDb
ND
a7.2 ± 0.9

EC90 (µM)
18.2 ± 14.6
20.7 ± 13.7
968 ± 65
18.3 ± 3.4
29.5 ± 8.7
195 ± 71.2
28.8 ± 11.0
21.0 ± 5.4
8.0 ± 2.1
13.2 ± 1.6
39.9 ± 0.2
19.3 ± 2.2
61.3 ± 34.7
18.0 ± 5.6
15.8 ± 3.4
20.8 ± 8.1
6.6 ± 4.7
ND
ND
33.0 ± 4.1

IC50 (µM)

Virus yield reduction assay

Not done.

For these compounds, averages were derived three separate experiments, instead from four experiments from which the averages of other compounds in the table were derived.

b

a

Promazine
10-(1-Ethyl-3-propyl-3-pyrrolidinylmethyl)-phenothiazine·HCl
Phenoxathiin
Chlorprothixene
10-(1-Ethyl-3-pyrrolidinymethyl)-phenothiazine·HCl
10-(Alpha-diethylaminopropionyl)-phenothiazine·HCl
Acetopromazine
Methotrimeprazine
Trifluoperazine dimaleate
Acetophenazine maleate
10-(1-Methyl-2-pyrrolidinymethyl)-phenothiazine·HCl
Propionylpromazine·HCl
Ethopropazine
Trifluopromazine·HCl
Perphenazine
2-Chloro-10-(3-chloropropanol)-10H-phenothiazine
Phenazine ethosulfate
Phenothiazine
Phenoxazine
Calpain Inhibitor IV

Compound

NIH-PA Author Manuscript
Table 1

NIH-PA Author Manuscript

In vitro SARS-CoV (strain Urbani) inhibitory activity of phenazines and phenothiazines

2.1
2.0
1.3
1.8
2.7
<1
1.3
1.7
<1
1.3
2.4
1.4
1.5
1.4
1.9
<1
1.1
–
–
3.3

SI
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Virus strain

Urbani
Frankfurt-1
CHUK-W1
Toronto-2
Urbani
Frankfurt-1
CHUK-W1
Toronto-2
Urbani
Frankfurt-1
CHUK-W1
Toronto-2
Urbani
Frankfurt-1
CHUK-W1
Toronto-2
Urbani
Frankfurt-1
CHUK-W1
Toronto-2

Compound

Acetophenazine maleate

Averages were derived from three separate experiments.

a

Calpain inhibitor IV

10-(1-Methyl-2-pyrrolidinymethyl)-phenothiazine·HCl

Promazine

Chlorprothixene

Table 2

8.1 ± 1.4
12.7 ± 3.1
9.6 ± 7.6
11.5 ± 3.7
12.0 ± 3.5
11.1 ± 3.4
12.6 ± 6.5
12.9 ± 3.6
14.0 ± 6.1
21.0 ± 15.4
15.6 ± 8.5
22.6 ± 12.8
12.9 ± 6.4
24.3 ± 7.4
19.0 ± 2.6
28.5 ± 8.1
2.6 ± 0.5
4.6 ± 2.1
2.6 ± 1.4
5.4 ± 1.4

EC50 ± S.D. (µM)

Neutral red uptake assaya

14.3 ± 6.4
18.0 ± 0.0
15.5 ± 3.1
13.7 ± 3.8
16.7 ± 1.5
13.0 ± 2.0
18.5 ± 4.9
15.8 ± 1.5
11.2 ± 5.7
33.7 ± 20.6
34.5 ± 20.4
34.0 ± 16.7
39.7 ± 14.0
32.3 ± 22.7
48.0 ± 10.5
42.3 ± 10.9
24.7 ± 7.0
44.0 ± 11.5
30.0 ± 4.1
45.0 ± 14.2

IC50 ± S.D. (µM)
1.8
1.4
1.6
1.2
1.4
1.2
1.5
1.2
<1
1.6
2.2
1.5
3.1
1.3
2.5
1.5
9.4
9.5
12.6
8.3

SI

12.3 ± 2.1
10.0 ± 5.2
11.2 ± 3.2
13.0 ± 0.0
10.5 ± 5.2
12.3 ± 0.6
12.1 ± 4.2
13.0 ± 1.0
7.8 ± 3.1
11.6 ± 6.3
16.5 ± 11.1
20.7 ± 9.5
28.3 ± 12.9
23.7 ± 6.0
31.3 ± 14.2
41.7 ± 4.0
7.2 ± 0.9
6.5 ± 3.6
6.5 ± 3.6
9.6 ± 3.1

EC90 ± S.D. (µM)

VYR assaya
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Table 3

Effects of i.p. promazine treatmenta on the replication of SARS-CoV (Urbani) in mice
Dosage/injection

NIH-PA Author Manuscript

100 mg/kg
50 mg/kg
10 mg/kg
1 mg/kg
Placebo
muIFN-α 100,000 (IU)

Toxicity controls survivor/Total

0/3c
3/3
3/3
3/3
3/3
3/3

Virus titer (Log10 CCID50/g) ± S.D.b

Virus titer
(Log10 CCID50/g)
± S.D.

Day 3

Day 7

Day 14

–
5.6 ± 1.0
5.6 ± 0.4
5.7 ± 0.3
5.7 ± 0.4
4.7 ± 0.4*

–
2.2 ± 3.1**
3.6 ± 0.2**
4.7 ± 0.9**
<0.75e

–
3.4 ± 0.1**
3.4 ± 0.0**
NDd

<0.75

*

p < 0.05 compared to the placebo controls.

**

p < 0.0001 compared to the placebo control.

a

Animals were treated at −4 h, then 8, 32, 56 h after virus exposure. Interferon was administered 12 prior to virus exposure.

b

Represents the average of two experiments.

c
All animals in both infected, treated and uninfected, treated groups died on day 3.
d

NIH-PA Author Manuscript

Not done.

e
Represents a titer of <0.75, the limits of detection for this assay.
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Table 4

Effects of therapeutic i.p. promazine treatment on the replication of SARS-CoV
(Urbani) in mice

NIH-PA Author Manuscript

Dosage/injection

Toxicity controls survivor/total

qd × 3, beginning 8 h after virus exposure
100 mg/kg
10 mg/kg
1 mg/kg
Placebo-1
qd × 1, beginning 8 h after virus exposure
100
10
1
Placebo-2
muIFN-α 100,000 (IU)c

Virus titer (Log10 CCID50/g) ± S.D.
Day 3

Day 7

0/3a
3/3
3/3
3/3

5.6 ± 0.0
5.8 ± 0.4
6.0 ± 0.6
5.5 ± 0.6

–
<0.75b
<0.75
<0.75

0/3a
3/3
3/3
3/3
3/3

5.6 ± 0.0
6.0 ± 0.6
5.4 ± 0.1
5.3 ± 0.4
4.7 ± 0.4

–
<0.75
<0.75
<0.75
<0.75

a

All animals in both infected, treated and toxicity groups died between days 3 and 7.

b

Represents a titer of <0.75, the limits of detection for this assay.

c
Interferon was administered 12 h prior to virus exposure.
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